In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Groups Uniting To Grow Global Regenerative Medicine Sector

This article was originally published in PharmAsia News

Executive Summary

South Korea, the U.S. and Japan are among the leading countries involved in the commercialization of stem cell therapies, with Japan’s Ministry of Economy, Trade and Industry (METI) estimating that the global regenerative medicines (RM) industry will grow strongly to reach a massive JPY53 trillion ($449 billion) by 2050. Groups in all three countries are now working closely to overcome the challenges in the sector, a recent conference in South Korea heard.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts